• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    1. (5E)-13,14,18,18,19,19-hexadehydro-3-oxa-6a-carba- prostaglandin-I2 derivatives of the general formula I see diagramm : EP0119949,P12,F2 in which R1 , R2 , R3 and R4 represent a hydrogen atom or an alkyl group having from 1 to 5 carbon atoms, and R5 represents an alkyl group having from 1 to 5 carbon atoms, and salts thereof with physiologically acceptable bases.
    公开号:SU1384196A3
    申请号:SU843700051
    申请日:1984-02-10
    公开日:1988-03-23
    发明作者:Скубалла Вернер；Радюхель Бернд；Форбрюген Хельмут；Штюрцебехер Клаус-Штефен；ХАБЕРЕЙ Мартин；Шиллингер Экехард；Таун Михаэль-Харольд
    申请人:Шеринг Аг (Фирма)；
    IPC主号:
    专利说明:


    s
    The invention relates to a process for the preparation of (5E) -13,14,18,18, 19,19-hexadehydro-3-oxa-6a-carba-prostaglandin-1g derivatives of the general formula
    HE
    about
    BUT
    sn
    BUT
    tb
    he
    sn.
    he
    where R is a methyl or ethyl group,.
    or their salts with tris- (oxymethyl) amine methano
    The aim of the invention is to create new compounds with improved pharmacological properties,
    PRI me R 1. (5E) - (16S) -13,14- Didigi schro-16,20-dimethyl-3-oxa-18,18
    19,19-tetradehydro-6a-carbaprosta-glandin-1.
    To a solution of 0.4 g of 2 - ((E) - (1S, 5S, 6S, 7R) -7- (tetrahydropyran-2-yloxy) - -6- (3S, 5S) -4-methyl-3- (tetragde - piran-2-yloxy) -nona-1,6-di-1-bicyclic 3,3,0 octane-3-ylidene-α-ethanol- -1 in 12 ml of tetrahydrofuran added 80 mg of 55% sodium hydride suspension (in mineral oil), after which the mixture is heated at reflux temperature for 1 h. Then a solution of 127 mg bromoacetic acid in 4 ml of tetrahydrofuran is added, the mixture is heated for 18 h at reflux temperature, diluted diethyl and extracted with 5% p The solution of sodium hydroxide is four times 30 ml each time. The resulting extract is acidified to pH 3 by adding a 10% aqueous solution of sulfuric acid at 0 ° C, followed by extraction with methylene chloride. The organic extract is shaken with a saturated solution of common salt, dried over magnesium sulfate and evaporated in vacuo to give 220 mg of 11,15-bis-tetrahydropyranyl ether (5E) - - (16S) - 13,14-didehydro-16,20-dimethyl-3-oxa-18, 18,19,19-tetrahydro0
    five
    0
    five
    0
    five
    0
    five
    0
    five
    -Ba-carbaprostaglandin- which for cleavage of the protective groups for 18 hours, stirred at 25 ° C with 15 ml of a mixture of acetic acid, water and tetrahydrofuran (65/35/10). The mixture is evaporated by the addition of toluene, and the residue is chromatographed on silica gel using as the eluent a mixture of ethyl ester of acetic acid and 0.1-1% acetic acid, to give 145 mg of the title compound as a colorless oily substance.
    IR spectrum (СНС1з) cm-,:. 3600, 3400 (broad), 2930, 2223, 1730, 1600, 1425, 1380.
    The starting material is obtained as follows.
    1ao (1R, 5S, 6S, 7R) - 3,3-Ethylenedioxy-7-benzoyloxy-6- (4S) -2- -brom-4-methyl-3-oxonone -1-it-6-vinyl -bicyclo (S, 3.0) octane.
    To a suspension of 3.57 g of sodium hydride (55% in mineral oil) in 360 ml of dimethyethane are added dropwise at 0 ° C a solution of 21.9 g of dimethyl ether 3-methyl-2-oxooct-5- phosphoric acid in 140 ml of dimethoxyethane, the mixture is stirred for 1 h at 0 ° C, then 14.56 g of N-bromosuccinimide, crushed into fine powder, is added to it. The mixture is stirred for 1 h at 0 ° C, mixed with a solution of 22.5 g (1R, 5S, 6RS, 7R) -3,3-ethylenedioxy-7-benzoyloxy-6-formyl-bicyclo 3,3,0 octane in 180 MP of dimethoxyethane, after which the mass is stirred for 4 h at 0 ° C. The reaction mixture is then diluted with 3 liters of diethyl ether, washed until the washing solution is neutral, with a saturated sodium chloride solution, dried over sodium sulfate and evaporated. in a vacuum. The residue is chromatographed on silica gel using a mixture of hexane and diethyl ether as an eluent. After chromatographing the diastereomeric mixed fractions three times, 8.1 g of (1R, 5S, 6S, 7R) -3,3-ethylenedioxy-7-benzoyloxy-6- (4R) -2-bromo-4- methyl-3-oxonon-1-en-6-ynyl 1-bicyclo 3,3,0} octane and in the form of a non-polar compound 7.4 g of this compound,
    the second is a colorless oily substance
    IR spectrum, cm -: 2935, 2878 ,, 1715, 1690, 1601, 1595, 1450, 1270, 948.
    1b. (1R, 5S, 6S, 7K) -3,3-Etsh1-dioxy-7 - (tetrahydropyran-2-yloxy) -6- t (3S, 4S) -2- bromo-4 - methyl-3 - (tetrahydropyran -2-yloxy) -non-1- -ene-b-inserh - bicyclo 3.3, octane. Q
    Pore is added to a solution of 7.4 g of the ketone prepared in Example 1a in 140 ml of methyl alcohol at -20 ° C. After stirring for 5–30 minutes, the mixture is immediately diluted with diethyl ether, washed with water to neutral wash water, dried over magnesium sulfate and charged in a vacuum.
    The crude product (mixture of 15 epimers) is dissolved in 300 ml of methyl alcohol, 2.95 g of potassium carbonate are added to the solution, after which 25 mixture is stirred for 21 hours under argon atmosphere. Immediately thereafter, the mixture is evaporated in vacuo, the residue is diluted with diethyl ether and washed with saturated sodium chloride solution until neutral. The solution is dried over magnesium sulphate and evaporated in vacuo. Chromatography on a column filled with silica gel using a mixture of diethyl ether and methylene chloride (7/3) and receiving methylene chloride (7/3) first gives 2.6 g of alcohol having 15 -. the configuration, as well as the polar component, is 2.1 g of alcohol, which is 15 sec / - the configuration (PG-nomenclature), which is a colorless oily substance.
    A solution containing 2.1 g of an alcohol obtained by analogy with the indicated 15, 20 mg of a pair of atoluene sulfonic acid and 1.4 g of dihydropyran in 50 ml of methylene chloride is stirred for 30 minutes at. Immediately after this, the reaction mixture is poured into a dilute sodium carbonate solution, extruded with diethyl ether. The organic phase is washed with water until neutral, dried over magnesium sulfate and evaporated in vacuo. After chromatography of the residue on
    45
    50
    Q
    50
    5 o
    five
    0
    silica gel is obtained upon use. as an eluent, a mixture of hexane and diethyl ether (6/4), 2.6 g of the title compound as a colorless oily substance.
    IR spectrum, cm-: 2939, 2877, 1450, 969, 948.
    1c „(1R, 5S, 6S, 7R) - 7 - (Tetrahydropyran - 2-yloxy) -6- (3S, 4S) - - 4 - methyl-3 - (tetrahydropyran - 2- -yloxy) -non- 1,6 - diinyl - bicyc-., 3,0 Zoctane - 3 - one.
    A solution of 290 mg of the compound obtained according to example 1b in 2.5 ml of dimethyl sulfoxide and 1 ml of tetrahydrofuran is mixed with 112 mg of potassium t-butylate, after which the mixture is stirred for 2 hours at 23 ° C. Then the reaction mixture was diluted with 10 ml of water and extracted three times with 10 ml of a mixture of diethyl ether and hexane (7/3), the extract was washed with water until neutral, dried over saturated sodium chloride solution and then evaporated in vacuo.
    The residue is stirred for 22 hours with 15 MP of a mixture of acetic acid, water and tetrahydrofuran (65/35/10), evaporated in vacuo with the addition of toluene and the residue is purified by chromatography on silica gel. 150 mg of an oily substance is extruded with diethyl ether, which is reacted with 5 MP of dichloromethane with 140 mg of dihydropyran and 1 mg of para-toluenesulfonic acid at: 0 ° C. After 30 hours, the reaction mixture was diluted with diethyl ether, shaken with 5% sodium hydrogen carbonate solution and saturated sodium chloride solution, dried over magnesium sulfate, and evaporated in vacuo. After chromatography on silica gel for use as. A mixture of hexane and diethyl ether (1/1) gave 185 mg of the title compound as a colorless oily substance.
    IR spectrum, cm-: 2940, 2876, 2216, 1733, 1020, 970.,
    1d. 2-t (E) - (lS, 5S, 6S, 7R) -7- - (Tetrahydropyran-2-yloxy) -6- - (35, 4s) -4-metr-3- (tetrahydropyran - 2-iolyoxy) -nona-1,6-diynyl - -bicyclo 3,3,0 octan-3-ylidene - ethanol - 1.
    To a solution of 529 mg of phosphorus acetic acid ethyl ester in 10 ml
    at 0 ° C, 225 mg of potassium t-butylate are added, the mixture is stirred for 10 minutes, mixed with a solution containing 0.6 g of ketoia prepared in Example 1c in 6 ml of toluene, after which the mixture is stirred for 22 hours at 23 ° s The mixture is then diluted with 150 ml of diethyl ether, shaken once with water and once with 20% sodium hydroxide solution, washed with water until neutral, dried over magnesium sulphate and evaporated in vacuo. The residue with a mixture of hexane and diethyl ether (6/4) is filtered through silica gel. The result is 0.58 g of the unsaturated ester as a colorless oily substance.
    IR spectrum, cm-: 2940, 2870, 221.2, 970.
    150 mg of lithium aluminum hydride is added in portions at 0 ° C to a stirred solution of 570 mg of the obtained ester in 25 ml of diethyl ether and the mixture is stirred for 30 minutes at 0 ° C. Excess reagent is diluted by adding 1-w-ethyl acetate in ethyl acetate. acid, add 1. ml of water, stir the mixture for 3 hours at 20 ° C, filter and evaporate in vacuo. The residue is chromatographed on silica gel using a mixture of diethyl ether and hexane (3/2) as an eluting agent. As a result, 140 mg of 2 - {(Z) - (IS, 5S, 6S, 7U-7- (tetrahydropyran-2-Sh1Oxy) -6- (3S, 4S) - 4 - methyl- 3- (tetrahydropyran-2- -yloxy) -nona-1,6-diynyl-bicyclo 3,3,0 octane - 3- or ethanol-1 price and 180 mg of the indicated compound as a colorless oily substance
    IR spectrum, 3620, 3450 (wide), 2940, 2860, 2212, 970
    EXAMPLE 2 (5E) - (16R) -13,14- -Dideg1Shro-1b5 20-dimethyl-3-oxa-18, 18,19,19-tetraheydro-6a-carba-prostaglandin-1.9.
    By analogy with example 1 of 0.6 2-UE) - (1S, 5S, 6s, 7R) - 7- (tetrahydropyran -2-yloxy) 6- t (3S, 4R) - 4-methyl- 3 - (tetrahydropyran-2- -yloxy) -one-1 "b-diynyl-bicyclo 3,3,0 octane-3-ylidene ethanol -1" receive 0.26 g of the specified
    Q o
    five . five
    0
    0
    five
    nor as a colorless oily substance.
    IR spectrum, cm: 3600, 3410 (broad), 2930, 2222, 1730, 1600, 1425, 1380.
    The starting material used to prepare the compound was prepared as follows.
    2a (1R, 5S, 68, 7R) -3,3-Ethylene-Dioxy-7- (tetrahydropyran -2-yloxy) -6- (38, 4R) -2- bromo-4-metsh-3 - - ( tetrahydropyran-2-yloxy) -ion -1- - en-6-ynyl-bicyclo 13,3,0-octane.
    By analogy with example 1 of 8 g of (1R, 5S, 6S, 7R) -3,3-ethylenedioxy-7-benzoyloxy-6 - (4R) -2-6poM-4-methyl-3-oxonon-1- ENEN-6-ynil 1 -bike 3, 3.0 octane (half a-st 16-methyl diastereomer of Example 1a) gives 2.9 g of the title compound as a colorless oily substance. IR spectrum, cm-: 2940, 2878, 1450, 970, 948.
    2b, (1R, 5S, 6S, 7R) - 7- (Tetrahydropyran -2-yloxy) -6 - (3S, 4R) -.-4-methyl-3 Chtetrahydropyran-2-yloxy) - nona - 1,6-diinsht - bicyclo 3,3,01 Octanone-3.
    By analogy with Example 1c, from 2.8 g of the compound obtained in Example 2a, 1.7 g of the title compound are obtained as a colorless oily substance.
    Zh-spectrum, cm-; 2940, 2875, 2215, 1738, 1021, 970.
    2c „2- (E) - (IS, 5S, 6S, 7R) -7- .- (Tetrahydropyran-2 -yloxy) -6-- (3S, 4R) -4-methyl-3- (tetrahydropyranone 2-yl6xn) - nona-1,6-diviyl - β-bicyclo 3,3,0-octane-3-ylidene - α-ethanol - 1.
    By analogy with example 1, from 1.6 g of the ketone obtained in Example 2b, after chromatographic separation of the isomers, 0.4 g of 2 - (Z) - (IS, 5S, 6S, 7R) -7- (TeT-rahydropyran-2 -yloxy) -6 -t (3S, 4R. - 4-methyl-3 - (tetrahydropyran-2 - - yloxy) -none -1,6 - diynyl - bicyclo 3,3,0 octane - 3-ylidene - - ethanol -1 in the form of a polar component 0.5 g of the compound indicated, which is a colorless oily substance.
    IR spectrum, cm-: 3600, 3440 (wide), 2942, 2860, 2212, 970,
    Froze (5E) - (16 RS) -13, 14-Didehydro-16-methyl-3-oxa-18.18,
    ten
    15
    713841968
    19,19-tetrahydro-. ba-carbaprostaglan alcohol at -40 ° C is added in portions of midin-I.2.5 g of sodium borohydride, after which
    By analogy with example 1 of 0.45 g, 2 - {(E - (IS, 5S, 65.7 U-7- (tetrahydropyran-2-yloxy) -6- (3S, 4RS) - - 4-metsh1- 3 - (tetrahydropyran-2- -yloxy) -oct-1,6-diynyl-bicyclo 3,3,0 octan-3-ylide} -ethanol-1 gives 0.2 g of the title compound as a colorless oily substance.
    IR spectrum, cm: 3610, 3400 (wide), 2932, 2221, 1730, 1600.
    The starting material used to prepare said compound is prepared as follows.
    Behind. (1R, 5S, 6S, 7R) - 3,3-Ethylenedioxy-7-benzoyloxy-6 - (4 RS) -2-bromo-4-methyl-3-oxooct-1-it-6-ynyl-bicyclo 3.3.0 octane,
    To a suspension of 1.81 g of sodium hydride in 180 ml of dimethoxyethane at 0 ° C is added dropwise a solution of 10.5 g
    dimethyl ester of 3 - methyl 2 - oxo 25 silica gel column using gep-5 - infosulfonic acid in 70 ml of nium dimethoxyethane as eluent, mix the mixture in diethyl ether and chloride for 1 hour at 0 ° C and then add. first methylene (7/3) are first poured to it 7.4 g of N-bromosuccinimide, crushed into fine powder. The mixture is stirred for 30 minutes at, mixed with a solution of 11.4 g (1R, 5S, 6R, 7R) -3.3-ethylen-dix-7-benzoyloxy-6-formylbicylo13.3.0 octane in 90 ml of dimethoxyethane
    20
    the reaction mixture is stirred for 30 minutes at -40 ° C. Immediately after this, the mixture is diluted with diethyl ether; washed with water until neutral, dried over magnesium sulfate and evaporated in vacuo. The crude product (mixture of 15-epimers) is dissolved in 200 ml of methyl alcohol, 2.5 g is added to the solution. potassium carbonate, after which the mixture is stirred for 17 hours at 23 ° C. under argon atmosphere. Directly thereafter, the mixture is evaporated in vacuo, the residue is diluted with diethyl ether, after which it is washed with concentrated sodium chloride solution until neutral. The organic phase is dried over magnesium sulphate and then evaporated to a vacuum. As a result of chromatography, it is filled30
    I, then the reaction mass is stirred for 2 hours at. Then, the reaction mixture is drunk in a fresh, ammonium chloride solution and extracted with diethyl ether. The organic extract is rinsed with water until neutral, dried over magnesium sulphate and evaporated in vacuo. After chromatography of the residue on silica gel with prpr-5
    40
    As an eluent, a mixture of hexane and diethyl ether (3/2) gives 8.2 g of unsaturated ketone as a colorless oil pattern, IR spectrum, cm: 2930, 2880, 1712, colored oily substance. 1688, 1602, 1595, 1450, 1275, 945.
    Zb "(1R, 5S, 6S, 7R) - 3,3-Ethylene-. dioxy-7- (tetrahydropyran-2-yloxy) -6- (3S, 4RS) -2-bromo-4-methyl-3g, 6 g of alcohol, having a 15-configuration, and also in the form of a polar component 2, 1 g of this compound (PG-Nomenclature 15 (/ - hydroxy), which is a colorless oily substance. Solution obtained from 1.6 g of c-alcohol, 16 mg of para-toluenesulfonic acid, 1.5 g of dihydropyran and 50 ml of methylene chloride, stirred for 35 minutes at 0 ° C. Immediately after this, the solution is diluted with diethyl ether, the solution is shaken with a dilute solution of sodium carbonate, washed with water until neutral, dried over magnesium sulphate and evaporated in vacuo. After chromatography of the residue on silica gel and using a mixture of hexane and diethyl ether (7/3) as an eluent, 2.17 g of the indicated compound is obtained as a non-IR spectrum, cm-: 2940, 2870, 1450, 1120, 1018, 965, 948.
    3c, (1R, 5S, 6S, 7R) - 7- (Tetra- (tetrahydropyran -2-yloxy) -oct-1- 55 hydropyran-2-Sh1oxy) -6 - (3S, 4RS) -en-6 insh 1 β-bicyclo 3.3.0 octane. - 4 methyl-3- (tetrahydropyran-2-ilokK to a solution of 5.9 g of the ketone prepared in Example 140 in 140 ml of methyl,
     si) octa - 1,6-diynyl-bicyclo 3,3,03 octanone - 3.
    the reaction mixture is stirred for 30 minutes at -40 ° C. Immediately after this, the mixture is diluted with diethyl ether; washed with water until neutral, dried over magnesium sulfate and evaporated in vacuo. The crude product (mixture of 15-epimers) is dissolved in 200 ml of methyl alcohol, 2.5 g is added to the solution. potassium carbonate, after which the mixture is stirred for 17 hours at 23 ° C. under argon atmosphere. Directly thereafter, the mixture is evaporated in vacuo, the residue is diluted with diethyl ether, after which it is washed with concentrated sodium chloride solution until neutral. The organic phase is dried over magnesium sulphate and then evaporated to a vacuum. As a result of chromatography, on a column filled with shshtigel, using a mixture of diethyl ether and methylene chloride (7/3) as an eluent, first
    colored oily substance.
    1.6 g of alcohol having a 15-configuration, as well as in the form of a polar component, 2.1 g of the indicated compound (PG-nomenclature 15 (/ - hydroxy), which is a colorless oily substance. A solution obtained from 1.6 g of α-alcohol, 16 mg of para-toluenesulfonic acid, 1.5 g of dihydropyran and 50 ml of methylene chloride, are stirred for 35 min at 0 ° C. Immediately after this, the solution is diluted with diethyl ether, the solution is shaken with diluted sodium carbonate solution, washed with water until neutral, dried over sulfate After chromatographing the residue on silica gel and using a mixture of hexane and diethyl ether (7/3) as an eluent, 2.17 g of the title compound is obtained as an oilless, oily substance.
    - IR spectrum, cm-: 2940, 2870, 1450, 1120, 1018, 965, 948.
    3c, (1R, 5S, 6S, 7R) - 7- (Tetra- 4 methyl-3- (tetrahydropyran-2-
     si) octa - 1,6-diynyl-bicyclo 3,3,03 octanone - 3.
    9 .13
    To a solution of 2.30 g of the compound obtained according to Example 3B in 23 ml of dimethyl sulfoxide and 10 ml of tetrahydrofuran were added 667 mg of potassium t-butylate, after which the mixture was stirred for 2 hours at 20 ° C. Then the reaction mixture is diluted by adding 100 ml of water and extracting with a mixture of diethyl ether and hexane (8/2) three times with 100 ml of the mixture, the extract is washed with 30 ml of water and 30 ml of saturated sodium chloride solution, dried over magnesium sulfate and evaporated in a vacuum. The residue is stirred for 75 hours with 75 ml of a mixture of acetic acid, water and tetrahydrofuran (65/35/10), the mixture is evaporated under vacuum, after which the residue obtained is purified by chromatography on silica gel. As a result of elution with diethyl ether, 1.05 g of an oily substance is obtained, which is reacted in 40 ml of dichloromethane with 0.91 g of dihydropyran and 10 mg of para-toluenesulfonic acid at. After 30 minutes, the mixture is diluted with diethyl ether, shaken with a solution of sodium hydrogencarbonate and with a saturated solution of sodium chloride, dried over magnesium sulfate and evaporated in vacuo. After chromatography on silica gel using a mixture of hexane and diethyl ether (1/1) as an eluent, 1.53 g of the above compound is obtained in the form of a colorless oily substance.
    IR Spectrum; cm-: 2942, 2876, 2210
    1737, 1018, 970, 905, 868.
    3d. 2 - (E) - (1S, 5S, 6S, 7R) -7- (Tetrahydropyran-2-yloxy) - 6 -1 (33, 4RS) - 4-methyl-3 - (tetrahydropyran-2-yloxy) - octa -1,6-di-ynyl - bishgklo 3,3,0 octan-3-ylidene - ethanol - 1.
    By analogy with Example Id, 1.4 g of the ketone prepared in Example 3c is obtained after chromatographic separation of the isomers of 0.37 g. 2 {(Z) - (1S, 5S, 6S, 7R) -7- (tetrahydropyran-2 ) - 6 -I (3S, 4RS) -4 - methyl-3 - (tetrahydropyran -2 - yloxy) - octa - 1.6 - diynyl 1-bit; cyclo, 350 octane - 3 - ylidene - - ethane - 1 and as a polar component, 0.48 g of the title compound.
    0 5 5
    0
    five
    0
    96.0
    which is a colorless, oily substance.
    IR spectrum, cm-: 3600, 3420 (wide), 2945, 2860, 2225.
    PRI me R 4. Salt (5E) - (16S) -13, 14 - dkdegidro - 16,20 - dimethyl-3-oxa - 18,18,19,19 -tetradehyde- - 6a carbaprostaglandin -Ij and tris- (hydroxymethyl) aminomethane.
    To a solution of 55 mg (5E) - (16S) -13, 14 - didepadro - 16.20 - dimethyl-3 - oxa - 18.18 j19.19 -, tetradehydro-ba - carbaprostaglandin-Ij; in 8 ml acetonitrile at 68 ° C. Add a ratvor 15 mg Tris - (hydroxymethyl) aminomethane in 0.05 ml of water. The mixture is cooled with stirring, after 16 hours the product is separated from the solvent by decantation, and the residue is dried in vacuo. As a result, 40 mg of the title compound are obtained as a viscous oily substance.
    IR spectrum (table. KBG), cm-: 3500 (wide), 2930, 2222, 1705 Ocher). ,
    The novel prostacyclin derivatives of general formula I are valuable biological active substances. They are able to lower blood pressure and expand the bronchi. In addition, they can be used to inhibit platelet aggregation. With a similar spectrum of activity in comparison with the corresponding prostaglandins, the target compounds (I) have a higher specificity and a much longer duration of activity fission. Compared to PGIj, they are more stable.
    The target compounds exhibit potent anti-platelet-coagulation activity, as well as more potent. Nizhayur1e pressure action than. Compounds (15E) - (16RS) - 16-methyl-3-oxa-18,18,19,19-tetra-dehydro-ba-carbaprostaglandin-Ij (II) and its methylated in 20 - position homolog (III). LDjo of the target product from example 1 10mg / kg. This value lies in the range of values for iloprost.
    The table shows the data of comparative experiments.
    II
    2 mg / kg
    III
    3.8
    (example 1)
    Note. Experiments were performed with 11,15-diacetate. After being metabolized in the liver, the diacetate is in the form of a diol. and therefore acts in the blood pressure lowering test as 11.15 - diol.
    权利要求:
    Claims (1)
    [1]
    Invention Formula
    1 to the "Method of creeping the derivatives (5E) - 13,14,18,18,19,19 - hexadeghydro-3-oxa-6a-carbaprostaglandin- - Ij of the general formula I
    ,
    l
    SNS FH., 6N
    where R is a methyl or ethyl group.
    PS 20 PD 31
    2 mg / kg
    PS 1-8 PD 29
    0.1 mg / kg
    PS 2.9 PD 43
    12
    or their salts with tris - (oxymethyl) aminomethane, characterized in that the compound of the general formula
    Sr
    OTGP OGPA
    where R is above,
    THP - tetrahydropyranyl residue,
    is subjected to esterification with bromoacetic acid in the presence of sodium hydride, and thereafter the tetrahydropyranyl groups are cleaved and, if necessary, the whole product is converted into salt with tris (oxymethyl) aminomethane.
    类似技术:
    公开号 | 公开日 | 专利标题
    SU1384196A3|1988-03-23|Method of producing derivatives of |-13,14,18,19,19-hexadehydro-3-oxa-6a-carboprostaglandin-1 sub two or salts thereof
    SU1367856A3|1988-01-15|Method of producing derivatives of carbacycline
    SU921465A3|1982-04-15|Method of producing prostane derivatives of salts thereof
    EP0045118A2|1982-02-03|Intermediates for the synthesis of bicyclo | heptanes and bicyclo | hept-2Z-enes
    SE453289B|1988-01-25|INTERMEDIATES FOR THE PREPARATION OF 9-DEOXI-9A METHYLENE OILS OF PGI? 712 AND PROCEDURE FOR THE PREPARATION OF THEM
    RU2267480C2|2006-01-10|Method and intermediate compounds for preparing latanoprost
    BG61261B1|1997-04-30|Process for the preparation of13,14-dihydro-15|-17-phenyl-18,19,20-trinor-pgf2? esters
    SU1316555A3|1987-06-07|Method for producing derivatives of carbacyclines or their additive-basic salts of tris-|-aminomethan
    SU818480A3|1981-03-30|Method of preparing pyrrolidone derivatives or the c5-epimers
    KR940003361B1|1994-04-21|Novel isocarbacyclins and process for production thereof
    SU1145926A3|1985-03-15|Method of obtaining carbacycline derivatives or their physiologically acceptable salts
    US4699989A|1987-10-13|7-fluoroprostaglandins and process for their production
    CA1076569A|1980-04-29|Prostaglandin analogues
    US4079055A|1978-03-14|Chemical reduction process
    CA1173051A|1984-08-21|Total synthesis of 1rs,4r,5rs-4-|-4-methyl-3,8-dioxabicyclo¬3.2.1| octane-1-acetic acid
    EP0116375B1|1986-11-12|-4-|-4-methyl-3,8-dioxybicyclo|octane-1-acetic acid and process for its preparation
    US5374745A|1994-12-20|Process for the synthesis of propargyl alcohols and their use for production of prostaglandin precursors
    CA1098126A|1981-03-24|Process for the preparation of 9,11,15-trihydroxy-13, 14-dehydro-prostaglandins and new prost-5-en-13-ynoic acid derivatives
    RU1830070C|1993-07-23|Method for producing allyl-7 -phenoxyacetylamino-3-methyl-1-carba |-3-cephem-4-carboxylate
    KR840000948B1|1984-07-01|Process for the preparation of 9-deoxy-9a-methylene isosteres of pgi2
    SU1380608A3|1988-03-07|Method of producing carbocycline derivatives or physiologically acceptable salts thereof
    US4390707A|1983-06-28|Bis-thioalkylfurans useful as cyclopentenone prostaglandin intermediates
    US5159102A|1992-10-27|7-thiaprostaglandins E, and process for producing same
    JP2872468B2|1999-03-17|Isocarbacycline derivatives, their production and photoaffinity labeling
    SU1218925A3|1986-03-15|Method of producing |-|-11,15 dihjdroxj-16,16,19-trimethyl-9-oxo-13,18-prostadien acid or |-|-11,15-dihydroxy-16,19-dimethyl-9-oxo-13,18-prostadien acid or their physiologically compatible salts
    同族专利:
    公开号 | 公开日
    JPS59157050A|1984-09-06|
    NO157060C|1988-01-13|
    DK55584A|1984-08-19|
    DK55584D0|1984-02-08|
    FI840635A|1984-08-19|
    DK155828C|1989-10-09|
    ES8500209A1|1984-11-01|
    HU191994B|1987-04-28|
    GR81961B|1984-12-12|
    YU24484A|1986-06-30|
    ZA841198B|1984-09-26|
    NO840595L|1984-08-20|
    JPH0611726B2|1994-02-16|
    FI840635A0|1984-02-16|
    IL70905A|1987-02-27|
    AU580728B2|1989-02-02|
    US5013758A|1991-05-07|
    FI78065C|1989-06-12|
    IE56703B1|1991-11-06|
    FI78065B|1989-02-28|
    CS103684A2|1989-11-14|
    IL70905D0|1984-05-31|
    NO157060B|1987-10-05|
    DE3306123A1|1984-09-06|
    AT38831T|1988-12-15|
    DK155828B|1989-05-22|
    DE3475302D1|1988-12-29|
    PH21468A|1987-10-28|
    EP0119949A1|1984-09-26|
    CA1251200A|1989-03-14|
    ES529636A0|1984-11-01|
    CS270552B2|1990-07-12|
    DD216448A5|1984-12-12|
    NZ207061A|1987-06-30|
    YU45173B|1992-05-28|
    AU2401584A|1984-08-23|
    IE840236L|1984-08-18|
    EP0119949B1|1988-11-23|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    DE3048906A1|1980-12-19|1982-07-15|Schering Ag, 1000 Berlin Und 4619 Bergkamen|NEW CARBACYCLINE, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICINAL PRODUCTS|
    DE3121155A1|1981-05-22|1982-12-09|Schering Ag, 1000 Berlin Und 4619 Bergkamen|NEW CARBACYCLINE, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICINAL PRODUCTS|DE3225287A1|1982-07-02|1984-01-05|Schering AG, 1000 Berlin und 4709 Bergkamen|NEW CARBACYCLINAMIDES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICINAL PRODUCTS|
    DE3608088C2|1986-03-07|1995-11-16|Schering Ag|Pharmaceutical preparations containing cyclodextrin clathrates of carbacyclin derivatives|
    DE3610556A1|1986-03-26|1987-10-01|Schering Ag|7-OXOPROSTACYCLINE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF|
    DE3727065A1|1987-08-11|1989-02-23|Schering Ag|METHOD FOR PRODUCING E / Z MIXTURES OF 2--OCTAN-3-YLIDEN) -ACetic Acid Derivatives With Predominant E or Z Portion|
    US5169960A|1987-08-11|1992-12-08|Schering Aktiengesellschaft|Process for the production of E/Z mixtures of 2--acetic acid derivatives with predominant E or Z portion|
    US5371284A|1987-09-03|1994-12-06|Schering Corporation|Phenyl acetylenic acetals|
    DE3835162A1|1988-10-13|1990-04-19|Schering Ag| -2 --2-HALOGEN-3-HYDROXY-1-ALKEN ) - 3-TRIALKYLSILYLOXY-7,7--BICYCLO--OCTANE COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF|
    DE3909329A1|1989-03-17|1990-09-20|Schering Ag|20-ALKYL-13,14,18,18,19,19-HEXADEHYDRO-3-OXA-ISOCARBACYCLIN DERIVATIVES AND THEIR PHARMACEUTICAL USE|
    DE3933523A1|1989-10-05|1991-04-11|Schering Ag|ANTIMETASTICALLY ACTIVE AGENTS|
    GB9011588D0|1990-05-24|1990-07-11|Wellcome Found|Prostaglandin analogues for use in medicine|
    DE4028864A1|1990-09-07|1992-03-12|Schering Ag|METHOD FOR PRODUCING E / Z MIXTURES OF 2--OCTAN-3-YLIDEN) -ACetic Acid Derivatives With Predominant Portion Of The E-ISOMER|
    EP0867185B1|1996-09-17|2002-06-12|Toray Industries, Inc.|Platelet function potentiator and method of curing platelet dysfunction|
    KR20070054644A|2004-07-26|2007-05-29|액테리온 파마슈티칼 리미티드|Treatment of pulmonary hypertension by inhaled iloprost with a microparticle formulation|
    CA2669763C|2006-11-16|2015-02-17|Bayer Schering Pharma Aktiengesellschaft|Ep2 and ep4 agonists as agents for the treatment of influenza a viral infection|
    JP2013508282A|2009-10-14|2013-03-07|ジェンムスファーマインコーポレイティド|Combination therapy treatment for viral infection|
    ES2525748T3|2009-11-13|2014-12-29|Toray Industries, Inc.|Therapeutic or prophylactic agent for diabetes|
    KR20160042039A|2013-08-09|2016-04-18|알데릭스, 인코포레이티드|Compounds and methods for inhibiting phosphate transport|
    US20200368223A1|2019-05-21|2020-11-26|Ardelyx, Inc.|Methods for inhibiting phosphate transport|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    DE19833306123|DE3306123A1|1983-02-18|1983-02-18|NEW CARBACYCLINE, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICINAL PRODUCTS|
    [返回顶部]